BRANFORD, Conn. / May 31, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced presentations at two upcoming industry conferences. Gloria Sheynkman, PhD, Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia’s lab will present a poster developed in collaboration with Quantum-Si at the American Society for Mass Spectrometry (ASMS) annual meeting being held June 2-6, 2024. Dr. Brian Reed, Head of Research at Quantum-Si will present at the European Society for Human Genetics (ESHG) annual meeting being held June 1-4, 2024.
Results of the study to be presented, by Natchanon Sittipongpittaya from Dr. Sheynkman’s lab at ASMS, represent the first integration of single-molecule detection methods with proteogenomics to detect proteotypic and isoform-selective peptides.
Long read transcriptomics (LR-RNA-seq) revealed multiple annotated and novel isoforms (i.e., spliceforms) of vimentin, TPM1 and TPM2. Like many alternatively spliced isoforms, much of the predicted protein sequences are highly overlapping and difficult to distinguish. Additionally, TPM1 and TPM2, being closely related paralogs, also have high sequence identity (87%). Using the Platinum platform, protein sequencing distinguished isoform-specific peptides for filament proteins involved in cancer and skeletal muscle diseases.
At ESHG, Dr. Reed will discuss the expanding role of Next-Generation Protein Sequencing™ (NGPS) in advancing biological research by enabling any researcher to sequence proteins in their lab. Quantum-Si’s protein sequencer, Platinum®, is a compact and affordable benchtop device that enables direct sequencing of proteins with single-amino-acid resolution using a simple workflow. NGPS is a transformative technology that enables direct interrogation of protein primary structure, post-translational modifications (PTMs), and protein isoform diversity.
Presentation details are as follows:
ASMS
Title: Integrated sequencing of transcripts and proteins at the single molecule level to detect isoforms and proteolytic peptides in filament biomarkers
Session: Proteomics: New Approaches
Authors: Gloria Shenykman, PhD and Natchanon Sittipongpittaya, both of the University of Virginia and Kenneth Skinner, PhD, Quantum-Si
Date and Time: June 3, 10:30 am - 12:30 pm and 1:30 - 2:30 pm PDT
ESHG
Title: Beyond the Genome: Unlocking Proteomic Discoveries with Quantum-Si’s Next-Generation Protein Sequencing™ Technology
Presenter: Brian Reed, PhD
Date and Time: Sunday, June 2, 8:30 -10:00 a.m. BST
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$0.75 |
Daily Change: | 0.009 1.22 |
Daily Volume: | 271,667 |
Market Cap: | US$91.690M |
October 30, 2024 September 04, 2024 August 07, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB